What type of cancer is sometimes treated with gefitinib erlotinib or afatinib?
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell lung cancer (NSCLC) with proven efficacy.
What cancers does gefitinib treat?
Gefitinib is a treatment for non small cell lung cancer (NSCLC) that has spread into the surrounding tissues (locally advanced) or to other parts of the body.
Is gefitinib first generation?
First-generation EGFR TKIs (gefitinib, erlotinib and icotinib) reversibly bind to EGFR and inhibit the binding of ATP to the TK domain. This block hampers cell proliferation, ultimately leading to cell death (11).
What is gefitinib used for?
Gefitinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer in patients who have certain types of abnormal epidermal growth factor (EGFR) genes, and did not receive cancer medicines in the past. Your doctor will perform a test before you take this medicine.
Is erlotinib more effective than gefitinib or afatinib?
We found no significant differences in the effectiveness of erlotinib, gefitinib, and afatinib among our Caucasian cohort of patients.
What is the prognosis of egfrgene mutations treated with erlotinib?
A comparison of the probability of PFS in NSCLC patients with EGFRgene mutations treated with erlotinib, gefitinib or afatinib is shown in Fig. 1. The median PFS was 10 months in patients treated with erlotinib, 9 months in patients treated with gefitinib, and 15 months in patients treated with afatinib (Table IV).
What is the difference between EGFR-TKI 26 and EGFR 26?
II or III 26 Type of EGFR-TKI (reversible vs. irreversible) Erlotinib and gefitinib 26 0.408 1.77 (0.603–5.603) 0.455 1.739 (0.41–7.41) Afatinib Not reached Type of EGFR-TKI (only reversible) Erlotinib 26 0.353 1.238 (0.768–1.768) Gefitinib 26 Type of EGFR-TKI (erlotinib vs afatinib) Erlotinib
What are the groups of patients treated with different EGFR-TKIs?
The groups of patients treated with different EGFR-TKIs were comparable with respect to their demographic, clinical, and molecular factors (Table II). The median age of all patients was 67 years and 55% patients were 67 years of age or older. 71% of EGFR-TKIs treated patients were women, and 43%-non-smokers.